AI Engines For more Details: Perplexity Kagi Labs You
Muscle Growth: Oxandrolone promotes protein synthesis in the body, leading to increased muscle mass and strength. It is used medically to help patients regain muscle mass lost due to prolonged illness or surgery.
Weight Gain: One of the primary medical uses of oxandrolone is to promote weight gain in patients who have experienced significant weight loss due to surgery, trauma, or chronic infections. It helps to increase lean body mass while minimizing the accumulation of fat tissue.
Bone Density: Oxandrolone has been shown to increase bone density, which can be beneficial for individuals at risk of osteoporosis or bone fractures, particularly postmenopausal women.
Treatment of Catabolic Conditions: It is used medically to counteract catabolic states (conditions where the body breaks down muscle tissue) associated with long-term corticosteroid therapy, chronic infections, or severe burns.
Anemia: Oxandrolone may be prescribed to treat anemia associated with bone marrow failure or certain chronic illnesses. It stimulates erythropoiesis (production of red blood cells) and can improve hemoglobin levels.
Wound Healing: In some cases, oxandrolone is used to promote wound healing and tissue repair in patients with severe burns or other traumatic injuries. It can aid in the regeneration of damaged tissues and accelerate the healing process.
Hormone Replacement Therapy: Oxandrolone is sometimes used as part of hormone replacement therapy in individuals with testosterone deficiency or delayed puberty. It can help stimulate puberty and promote the development of secondary sexual characteristics.
Improved Quality of Life: By promoting weight gain, muscle strength, and overall well-being, oxandrolone can improve the quality of life for individuals recovering from illness, injury, or surgical procedures.
Side Effects: Like other anabolic steroids, oxandrolone can cause side effects, including liver toxicity, cardiovascular complications (such as hypertension and changes in cholesterol levels), and psychiatric effects (such as mood swings, aggression, or depression).
Masculinizing Effects: In women, oxandrolone may cause masculinizing effects such as deepening of the voice, enlargement of the clitoris, and changes in menstrual cycles. These effects are dose-dependent and reversible upon discontinuation of the drug.
Children and Adolescents: Oxandrolone should be used with caution in children and adolescents, as it can interfere with growth and maturation if used for prolonged periods. It should only be prescribed under the supervision of a pediatric endocrinologist.
Abuse Potential: Due to its performance-enhancing effects, oxandrolone is sometimes abused by athletes and bodybuilders to improve muscle mass and strength. Misuse of the drug can lead to serious health consequences and is prohibited in competitive sports.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
Acne | 0.3 | 0.3 | |
ADHD | 1 | 1 | |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.4 | 0.5 |
Allergic Rhinitis (Hay Fever) | 2.5 | 0.8 | 2.13 |
Allergies | 2.5 | 1.6 | 0.56 |
Allergy to milk products | 0.8 | 1.3 | -0.63 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 3 | 2.1 | 0.43 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.3 | 3 |
Ankylosing spondylitis | 2.4 | 0.7 | 2.43 |
Anorexia Nervosa | 0.9 | 0.9 | 0 |
Antiphospholipid syndrome (APS) | 0.9 | 0.3 | 2 |
Asthma | 2.1 | 0.6 | 2.5 |
Atherosclerosis | 1 | 0.2 | 4 |
Atrial fibrillation | 1.7 | 1.9 | -0.12 |
Autism | 3.6 | 3.7 | -0.03 |
Autoimmune Disease | 0.9 | 0.2 | 3.5 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.1 | 1.1 | |
Bipolar Disorder | 1.8 | 1.8 | |
Brain Trauma | 0.3 | 0.3 | 0 |
Breast Cancer | 0.5 | 0.5 | |
Cancer (General) | 0.3 | 0.5 | -0.67 |
Carcinoma | 2.9 | 1.3 | 1.23 |
Celiac Disease | 1 | 1.6 | -0.6 |
Cerebral Palsy | 0.8 | 0.3 | 1.67 |
Chronic Fatigue Syndrome | 1.5 | 2.4 | -0.6 |
Chronic Kidney Disease | 2 | 0.3 | 5.67 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.6 | 0.83 |
Chronic Urticaria (Hives) | 1.4 | 0.3 | 3.67 |
Coagulation / Micro clot triggering bacteria | 1.7 | 0.3 | 4.67 |
Cognitive Function | 1.6 | 0.5 | 2.2 |
Colorectal Cancer | 3.5 | 1.1 | 2.18 |
Constipation | 0.9 | 0.9 | |
Coronary artery disease | 1.3 | 0.4 | 2.25 |
COVID-19 | 3.8 | 2.5 | 0.52 |
Crohn's Disease | 3.7 | 1.7 | 1.18 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.9 | 0.3 | 2 |
d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
deep vein thrombosis | 1.2 | 0.6 | 1 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 3.7 | 2.9 | 0.28 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 1.5 | 1.1 | 0.36 |
Endometriosis | 2.5 | 0.3 | 7.33 |
Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
Epilepsy | 2.3 | 1.3 | 0.77 |
erectile dysfunction | 1.9 | 1.9 | |
Fibromyalgia | 2.1 | 0.8 | 1.63 |
Functional constipation / chronic idiopathic constipation | 2.3 | 1.3 | 0.77 |
gallstone disease (gsd) | 2.3 | 0.3 | 6.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.3 | 1 |
Generalized anxiety disorder | 1.9 | 0.8 | 1.37 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 1.6 | 0.2 | 7 |
Graves' disease | 0.7 | 1.2 | -0.71 |
Gulf War Syndrome | 0.5 | 0.4 | 0.25 |
Halitosis | 1 | 0.3 | 2.33 |
Hashimoto's thyroiditis | 1.2 | 0.6 | 1 |
Heart Failure | 2.4 | 2.4 | |
hemorrhagic stroke | 1.3 | 1.3 | |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
High Histamine/low DAO | 1 | 1 | |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 0.9 | 0.7 | 0.29 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 2.7 | 1.3 | 1.08 |
Hypoxia | 2.9 | 0.3 | 8.67 |
IgA nephropathy (IgAN) | 1.3 | 0.9 | 0.44 |
Inflammatory Bowel Disease | 4.1 | 2.4 | 0.71 |
Insomnia | 1.2 | 0.6 | 1 |
Intelligence | 0.8 | 0.3 | 1.67 |
Intracranial aneurysms | 1 | 1 | |
Irritable Bowel Syndrome | 3 | 1.3 | 1.31 |
ischemic stroke | 1.3 | 0.9 | 0.44 |
Liver Cirrhosis | 3.4 | 2.3 | 0.48 |
Long COVID | 2.7 | 2.2 | 0.23 |
Lung Cancer | 0.9 | 0.6 | 0.5 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 1.1 | 1.1 | |
ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
ME/CFS without IBS | 0.6 | 0.9 | -0.5 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.3 | 0.3 | |
Metabolic Syndrome | 4.1 | 2.5 | 0.64 |
Mood Disorders | 3.1 | 2.3 | 0.35 |
multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
Multiple Sclerosis | 3.4 | 2.1 | 0.62 |
Multiple system atrophy (MSA) | 0.2 | 0.2 | |
myasthenia gravis | 0.9 | 0.2 | 3.5 |
neuropathic pain | 0.7 | -0.7 | |
Neuropathy (all types) | 0.3 | 1 | -2.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 0.3 | 9.67 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 3.7 | 2.4 | 0.54 |
obsessive-compulsive disorder | 2.1 | 1.5 | 0.4 |
Osteoarthritis | 1.9 | 0.6 | 2.17 |
Osteoporosis | 1.1 | 1.2 | -0.09 |
pancreatic cancer | 1.4 | 0.6 | 1.33 |
Parkinson's Disease | 2.5 | 3 | -0.2 |
Polycystic ovary syndrome | 2.9 | 1.1 | 1.64 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
primary biliary cholangitis | 0.9 | 0.8 | 0.13 |
Primary sclerosing cholangitis | 1.7 | 0.7 | 1.43 |
Psoriasis | 1 | 1 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.4 | 1.21 |
Rosacea | 0.2 | -0.2 | |
Schizophrenia | 2.9 | 0.9 | 2.22 |
scoliosis | 0.3 | 0.3 | 0 |
Sjögren syndrome | 1.6 | 1.3 | 0.23 |
Sleep Apnea | 0.9 | 0.3 | 2 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
Stress / posttraumatic stress disorder | 2.1 | 0.7 | 2 |
Systemic Lupus Erythematosus | 2.6 | 2.6 | |
Tic Disorder | 0.3 | 0.8 | -1.67 |
Tourette syndrome | 0.9 | 0.3 | 2 |
Type 1 Diabetes | 2.4 | 0.8 | 2 |
Type 2 Diabetes | 3.6 | 2.9 | 0.24 |
Ulcerative colitis | 3.9 | 1.9 | 1.05 |
Unhealthy Ageing | 2.1 | 0.4 | 4.25 |
Vitiligo | 1.1 | 0.6 | 0.83 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]